Cannara Biotech Inc.
Cannara Biotech Inc.
- Market cap
- $198.06M
- P/E ratio
- 17.87
Your view on LOVE.TO
Overview
What the company does, where it operates, and who runs it.
About Cannara Biotech Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Zohar Krivorot
- Headquarters
- 333 Decarie Blvd., Saint-Laurent, QC, CA
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Zohar Krivorot
- Headquarters
- 333 Decarie Blvd., Saint-Laurent, QC, CA
Cannara Biotech Inc., alongside its affiliated entities, specializes in the indoor cultivation, processing, and distribution of cannabis and related products across Canada. The company operates with a dual business model, encompassing both cannabis operations and real estate activities.
Its diverse product portfolio is marketed under distinct brand names such as TRIBAL, nugz, and ORCHID CBD. Distribution is managed through both wholesale channels and online retail platforms. Established in 2017, Cannara Biotech Inc. maintains its headquarters in Saint-Laurent, Canada.
Stock Data
Price chart, volume, and trading data.
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Cannara Biotech Inc. from FRC's valuation model, read against the market price. LOVE.TO last traded at C$2.00, 17.9× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Cannara Biotech Inc.. Starting points for Cannara Biotech Inc.: P/E 17.9, EPS C$0.11, beta 0.33 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Cannara Biotech Inc.. Trailing twelve-month EPS for Cannara Biotech Inc. stands at C$0.11. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This quarterAug 2026 | Next quarterNov 2026 | This yearYear to Aug 2026 | Next yearYear to Aug 2027 |
|---|---|---|---|---|
| Average estimate | CAD 0.04 | CAD 0.05 | CAD 0.12 | CAD 0.21 |
| Lowest estimate | CAD 0.04 | CAD 0.05 | CAD 0.12 | CAD 0.20 |
| Highest estimate | CAD 0.04 | CAD 0.05 | CAD 0.12 | CAD 0.23 |
| Number of analysts | 1 | 1 | 3 | 3 |
| A year ago | — | CAD 0.01 | CAD 0.14 | — |
| Growth vs a year ago | — | +400.0% | −14.3% | — |
Revenue estimates
| Total | This quarterAug 2026 | Next quarterNov 2026 | This yearYear to Aug 2026 | Next yearYear to Aug 2027 |
|---|---|---|---|---|
| Average estimate | CAD 34.55M | CAD 35.48M | CAD 123.38M | CAD 145.97M |
| Lowest estimate | CAD 33.11M | CAD 34.11M | CAD 122.19M | CAD 142.48M |
| Highest estimate | CAD 35.91M | CAD 36.51M | CAD 124.99M | CAD 149.50M |
| Number of analysts | 3 | 3 | 4 | 4 |
| A year ago | — | CAD 30.11M | CAD 107.32M | — |
| Growth vs a year ago | — | +17.8% | +15.0% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Cannara Biotech Inc.. Cannara Biotech Inc. has reported as a listed company since 2019. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| CRDL.TOCardiol Therapeutics Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | $164.1M | ||
| DB.VDecibel Cannabis Company Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | $54.4M | ||
| GRIN.CNGrown Rogue International Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | $149.7M | ||
| HBP.TOHelix BioPharma Corp. | Healthcare | Biotechnology | $65.7M | ||
| HLS.TOHLS Therapeutics Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | $116.3M | ||
| JUSH.CNJushi Holdings Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | $165.2M | ||
| MSCL.TOSatellos Bioscience Inc. | Healthcare | Biotechnology | $182.9M | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| VIVXFAvivagen Inc. | Healthcare | OTC | $7,769 | ||
| VLS.AXVita Life Sciences Limited | Healthcare | ASX | — | ||
| VM.VVoyageur Pharmaceuticals Ltd. | Healthcare | TSXV | $23.1M | ||
| VPHIFValeo Pharma Inc. | Healthcare | OTC | $9,866 | ||
| VREOFVireo Growth Inc. | Healthcare | OTC | $502.5M | ||
| VRNOVerano Holdings Corp. | Healthcare | OTC | $426.9M | ||
| VRNO.NEVerano Holdings Corp. | Healthcare | NEO | — | ||
| VRTHFIndigenous Bloom Hemp Corp. | Healthcare | OTC | $131,146 | ||
| VTRSViatris Inc. | Healthcare | NASDAQ | $23.3B | ||
| VYYRFVoyageur Pharmaceuticals Ltd. | Healthcare | OTC | $22.5M | ||
| WEED.TOCanopy Growth Corporation | Healthcare | TSX | $323.7M | ||
| WIBFFWest Island Brands Inc. | Healthcare | OTC | $60,061 | ||

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Cannara Biotech Inc.